Novel Method for Risk Stratification of Major Adverse Clinical Events Using Pre- and Post-Ablation Left Atrial Volume Index in Patients With Persistent Atrial Fibrillation DOI Open Access
Hironori Ishiguchi, Yasuhiro Yoshiga, Akihiko Shimizu

et al.

Circulation Reports, Journal Year: 2024, Volume and Issue: 6(10), P. 415 - 423

Published: Sept. 6, 2024

The relationship between changes in the left atrial volume index (LAVI) post-catheter ablation (CA) and long-term prognostic events patients with persistent fibrillation (AF) remains unclear. We evaluated incidence of major adverse clinical (MACE), including all-cause death, unplanned heart failure hospitalization, cardiovascular hospitalization using pre- post-CA LAVI.

Language: Английский

Heart failure with preserved ejection fraction and atrial fibrillation: epidemiology, pathophysiology, and diagnosis interplay DOI
Veraprapas Kittipibul, Carolyn S.P. Lam

Heart Failure Reviews, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 24, 2025

Language: Английский

Citations

3
Atrial Functional Mitral Regurgitation: Definition, Mechanisms, and Treatment Perspectives DOI
Sebastiaan Dhont, Sébastien Deferm, Philippe B. Bertrand

et al.

Current Cardiology Reports, Journal Year: 2025, Volume and Issue: 27(1)

Published: Jan. 11, 2025

Language: Английский

Citations

0
The interaction between atrial fibrillation and mitral regurgitation: Insights from the CABANA randomized clinical trial DOI Creative Commons
Sebastiaan Dhont, Philippe B. Bertrand,

Jonas Erzeel

et al.

European Journal of Heart Failure, Journal Year: 2025, Volume and Issue: unknown

Published: April 21, 2025

Abstract Aims Atrial fibrillation (AF) and mitral regurgitation (MR) frequently coexist. While catheter ablation is a key rhythm‐control strategy in AF, its impact on MR severity remains uncertain. This study evaluates the effects of AF recurrence, functional status, progression patients with baseline MR. Methods results sub‐analysis included 1423 (65% overall CABANA cohort) available echocardiography. Participants were randomized to or pharmacological therapy. The primary endpoint was composite all‐cause mortality cardiovascular hospitalization. Secondary endpoints changes severity, status. At baseline, 722 (52%) had MR, including 582 mild 140 ≥moderate characteristics suggestive an atrial mechanism. Catheter significantly reduced recurrence compared therapy (odds ratio [OR] 0.56, 95% confidence interval [CI] 0.50–0.62, p < 0.001). presence absence did not interact randomization terms neutral effect hospitalization ( for interaction = 0.115). Baseline increased risk (OR 1.46, CI 1.40–1.74, However, benefit status greater those without Follow‐up echocardiography n 248) showed reduction group versus drug 0.040). Conclusion superior rhythm control may reduce over time. These findings highlight ablation's potential structural symptomatic benefits, pending specifically designed clinical trials.

Language: Английский

Citations

0
The Inextricable Link Between Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction DOI
Jeanne E. Poole, April Stempien‐Otero

JACC Heart Failure, Journal Year: 2025, Volume and Issue: 13(5), P. 795 - 797

Published: May 1, 2025

Language: Английский

Citations

0
Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation DOI
Paul M. Haller, Petr Jarolı́m, Michael G. Palazzolo

et al.

Journal of the American College of Cardiology, Journal Year: 2024, Volume and Issue: 84(16), P. 1528 - 1540

Published: Sept. 2, 2024

Language: Английский

Citations

3
Novel Method for Risk Stratification of Major Adverse Clinical Events Using Pre- and Post-Ablation Left Atrial Volume Index in Patients With Persistent Atrial Fibrillation DOI Open Access
Hironori Ishiguchi, Yasuhiro Yoshiga, Akihiko Shimizu

et al.

Circulation Reports, Journal Year: 2024, Volume and Issue: 6(10), P. 415 - 423

Published: Sept. 6, 2024

The relationship between changes in the left atrial volume index (LAVI) post-catheter ablation (CA) and long-term prognostic events patients with persistent fibrillation (AF) remains unclear. We evaluated incidence of major adverse clinical (MACE), including all-cause death, unplanned heart failure hospitalization, cardiovascular hospitalization using pre- post-CA LAVI.

Language: Английский

Citations

1